OUR SCIENCE
PARTNERING
Unlocking Immune Potential with
Innovative Metabolic Reprogramming
Pilatus Biosciences pioneers innovative therapies using first-in-class antibodies and bifunctional proteins to target metabolic checkpoints, reprogramming the immune microenvironment to address cancer and immune-related diseases.
LEARN moreOngoing Phase 1 Clinical Trials with our Lead Candidate PLT012
PLT012 is a first-in-class anti-CD36 monoclonal antibody and metabolic checkpoint inhibitor designed to target lipid-mediated immunosuppression. It is being evaluated in an ongoing Phase 1 clinical trial in patients with advanced solid tumors, marking Pilatus Biosciences’ transition into clinical-stage development.
More InformationPLT012: FDA Designations
Fast Track Designation
Granted by the FDA to facilitate development and expedite review of PLT012 for hepatocellular carcinoma, a serious condition with high unmet medical need.
Orphan Drug Designation
Granted by the FDA to support the development of PLT012 for hepatocellular carcinoma and intrahepatic bile duct cancer, including regulatory incentives and potential market exclusivity.
.png)
“At Pilatus Biosciences, innovation and integrity drive our mission to transform disease treatment. Through excellence and collaboration, we shape a future of groundbreaking breakthroughs together.”
Raven Lin | Co-Founder and Chief Executive Officer of Pilatus Biosciences
Mechanism of Action:
Targeting Maladaptive Metabolism
Mission
Our mission is to create innovative immunotherapies that unlock the immune system's potential and improve lives by turning once-untreatable diseases into manageable conditions.
Partners
Latest News
Partner with Us to Advance Immune Innovation
We are currently seeking strategic partners and investors to accelerate the development and commercialization of our lead candidate, PLT012, and expand our pioneering pipeline.
If you are exploring high-potential investment opportunities in biotech front or looking to collaborate on cutting-edge medical science, Pilatus invites you to connect with us!
Unlocking Immune Potential with
Innovative Metabolic Reprogramming
Pilatus Biosciences
Pilatus Biosciences SA
Route de la Corniche 6
1066 Epalinges
Vaud - SWITZERLAND
Route de la Corniche 6
1066 Epalinges
Vaud - SWITZERLAND
Pilatus Biosciences Corp
17F-1, No. 508, Section 7,
Zhongxiao East Road,
Nangang District,
Taipei City 115, Taiwan
17F-1, No. 508, Section 7,
Zhongxiao East Road,
Nangang District,
Taipei City 115, Taiwan
© 2025 Pilatus Biosciences. All Rights Reserved.